GH Research (GHRS) Convertible Debt (2025)
GH Research (GHRS) recorded quarterly Convertible Debt of $44.2 million in Q3 2025, down 19.31% quarter-over-quarter from $54.8 million in Q2 2025.
GH Research (GHRS) Convertible Debt (2025) Analysis & Trends
GH Research's Convertible Debt history runs 1 years deep, the most recent figure standing at $44.2 million for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 44.23 Mn |
| Jun 30, 2025 | 54.81 Mn |